T Tammela

Author PubWeight™ 43.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995 6.60
2 Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995 3.98
3 Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997 3.37
4 Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998 2.90
5 Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999 2.45
6 The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003 1.55
7 Postoperative urinary retention. I. Incidence and predisposing factors. Scand J Urol Nephrol 1986 1.29
8 Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998 1.16
9 A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. Clin Cancer Res 2000 1.16
10 A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998 1.13
11 European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999 1.09
12 Biodegradable self-reinforced polyglycolic acid spiral stent in prevention of postoperative urinary retention after visual laser ablation of the prostate-laser prostatectomy. J Urol 1995 1.02
13 Postoperative urinary retention. II. Micturition problems after the first catheterization. Scand J Urol Nephrol 1986 1.01
14 Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 1997 0.95
15 A randomized study to compare biodegradable self-reinforced polyglycolic acid spiral stents to suprapubic and indwelling catheters after visual laser ablation of the prostate. J Urol 1997 0.94
16 Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000 0.93
17 Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993 0.92
18 Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 1998 0.90
19 Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 1995 0.89
20 Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol 1992 0.88
21 Prevention of prolonged voiding problems after unexpected postoperative urinary retention: comparison of phenoxybenzamine and carbachol. J Urol 1986 0.88
22 Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 1997 0.86
23 Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001 0.83
24 Efficacy and safety of clean intermittent catheterization in adults. Eur Urol 1991 0.80
25 Bioabsorbable and biodegradable stents in urology. J Endourol 1997 0.79
26 Aetiology of priapism in 207 patients. Eur Urol 1995 0.79
27 Erectile dysfunction as a risk factor for coronary heart disease: implications for prevention. Int J Clin Pract 2007 0.79
28 Three-year results of the Finnish prostate cancer screening trial. J Natl Cancer Inst 2001 0.79
29 The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. Prostate Cancer Prostatic Dis 2011 0.78
30 Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. Br J Cancer 1996 0.77
31 High cell proliferation activity determined by DNA flow cytometry predicts poor prognosis after relapse in prostate cancer. Eur J Cancer 1994 0.77
32 Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer. Ann Chir Gynaecol 2001 0.76
33 Immunohistochemical localization of carbonic anhydrase isoenzymes in the human male reproductive tract. Histochemistry 1990 0.75
34 [Management of scrotal hydrocele by sclerotherapy]. Duodecim 1988 0.75
35 Antibiotic prophylaxis in patients with urinary retention undergoing transurethral prostatectomy. Ann Chir Gynaecol 1997 0.75
36 [Urethral carcinoma in men--a difficult diagnostic problem]. Duodecim 1989 0.75
37 [Male sexual dysfunction]. Duodecim 2001 0.75
38 Intravesical prostaglandin F2 for promoting bladder emptying after surgery for female stress incontinence. Br J Urol 1987 0.75
39 [When is an andrologist needed?]. Duodecim 2001 0.75
40 Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumours. Scand J Urol Nephrol 1991 0.75
41 [Surgical management of impotence]. Duodecim 1988 0.75
42 [Management of urinary incontinence by an internal prosthesis]. Duodecim 1988 0.75
43 Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. J Urol 2001 0.75
44 [About Psa-screening]. Duodecim 1996 0.75
45 The dilemma of suspicious urine cytology in patients being followed for bladder cancer. Ann Chir Gynaecol 2001 0.75
46 Ethanolamine oleate as a sclerosant for testicular hydroceles and epididymal cysts. Br J Urol 1988 0.75
47 [Ultrasonic confirmation of scrotal pathology]. Duodecim 1989 0.75
48 [Treatments of benign prostatic hypertrophy and their cost-benefit relationship]. Duodecim 2000 0.75
49 Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer. Eur Urol 1988 0.75
50 Efficacy and safety of bladder neck incision in patients with benign prostatic hyperplasia. Ann Chir Gynaecol Suppl 1993 0.75
51 [Prostaglandin management of urine retention after surgery for incon- tinence]. Duodecim 1988 0.75
52 Prospective randomized open study between ciprofloxacin and a combination of sulfadiazine and trimethoprim in antibiotic prophylaxis in connection with transurethral prostatectomy. Scand J Urol Nephrol 1996 0.75
53 [Why screen for prostate cancer in Finland?]. Duodecim 1996 0.75
54 Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment. Br J Urol 1997 0.75
55 Ranitidine versus anticholinergic/antacid for duodenal ulcer. A randomized, endoscopically controlled, single-blind multicentre trial. Scand J Gastroenterol 1985 0.75